Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system

Behavioural Brain Research

Volumn 284, Issue , 2015, Pages 24-36

  Kruk Slomka, Marta ^a   Michalak, Agnieszka ^a   Biala, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cholinergic system; Depression; Endocannabinoid system; Forced swimming test; Mice

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID RECEPTOR; ENDOCANNABINOID; NICOTINE TARTRATE; OLEAMIDE; SCOPOLAMINE; SODIUM CHLORIDE; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; ANTIDEPRESSANT AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; INDOLE DERIVATIVE; IODOPRAVADOLINE; LIGAND; NICOTINE; OLEIC ACID; OLEYLAMIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SCOPOLAMINE BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; FORCED SWIM TEST; MALE; MOUSE; NONHUMAN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; CANNABINOIDS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; INDOLES; LIGANDS; MALE; MICE; MOTOR ACTIVITY; NICOTINE; OLEIC ACIDS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SCOPOLAMINE HYDROBROMIDE; SWIMMING;

EID: 84923062642     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.01.051     Document Type: Article

References (91)

1. Agrawal R., Tyagi E., Saxena G., Nath C. Cholinergic influence on memory stages: a study on scopolamine amnesic mice. Indian J Pharmacol 2009, 41:192-196.
2. Ashton C.H., Moore P.B., Gallagher P., Young A.H. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 2005, 19(3):293-300.
3. Aso E., Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol 2014, 5:37.
4. Aso E., Juvés S., Maldonado R., Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheim Dis 2013, 35(4):847-858.
5. Balerio G.N., Aso E., Maldonado R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 2006, 184(3-4):504-513.
6. Bejar C., Wang R.H., Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 1999, 383:231-240.
7. Biala G., Kruk M. Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice. Behav Brain Res 2008, 192:198-202.
8. Blaas K. Treating depression with cannabinoids. Cannabinoids 2008, 3(2):8-10.
9. Blokland A. Acetylcholine: a neurotransmitter for learning and memory?. Brain Res Brain Res Rev 1995, 21:285-300.
10. Bolognini D., Cascio M.G., Parolaro D., Pertwee R.G. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 2012, 165(8):2561-2574.
11. Brown A.J. Novel cannabinoid receptors. Br J Pharmacol 2007, 152(5):567-575.
12. Brusco A., Tagliaferro P., Saez T., Onaivi E.S. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 2008, 62(12):944-949.
13. Campbell V.A., Gowran A. Alzheimer's disease; taking the edge off with cannabinoids?. Brit J Pharmacol 2007, 152(5):655-662.
14. Castañé A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
15. Chen Z., Zhong C. Oxidative stress in Alzheimer's disease. Neurosci Bull 2014, 30(2):271-281.
16. Cohen C., Perrault G., Griebel G., Soubrié P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonists, rimonabant. Neuropsychopharmacology 2005, 30:145-155.
17. Deiana S., Platt B., Riedel G. The cholinergic system and spatial learning. Behav Brain Res 2011, 221:389-411.
18. Di Marzo V., Breivogel C., Bisogno T., Melck D., Patrick G., Tao Q., et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol 2000, 406:363-374.
19. Drevets W.C., Zarate C.A., Furey M.L. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 2013, 73:1156-1163.
20. El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., et al. Antidepressant-like effect of δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010, 95(4):434-442.
21. Fedorova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L.O., Boger D.L., et al. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J Pharmacol Exp Ther 2001, 299(1):332-342.
22. Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A.J. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 1997, 17(15):5747-5759.
23. García-Gutiérrez M.S., García-Bueno B., Zoppi S., Leza J.C., Manzanares J. Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA-A receptors. Brit J Pharmacol 2012, 165(4):951-964.
24. Gessa G.L., Mascia M.S., Casu M.A., Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids:reversal by SR 141716A. Eur J Pharmacol 1997, 327:R1-R2.
25. Gifford A.N., Ashby C.R. Electrically-evoked acetylcho-line release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR-141716A. J Pharmacol Exp Ther 1996, 277:1431-1436.
26. Gifford A.N., Tang Y., Gatley S.J., Volkow N.D., Lan R., Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997, 238:84-86.
27. Gifford A.N., Bruneus M., Gatley S.J., Volkow N. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Brit J Pharmacol 2000, 131:645-650.
28. Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol Lett 2004, 25(1-2):14-23.
29. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
30. Hasselmo M.E., Bower J.M. Acetylcholine and memory. Trends Neurosci 1993, 16(6):218-222.
31. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006, 16:710-715.
32. Hayase T. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs. Neurosci 2007, 8:76.
33. Hill M.N., Gorzałka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in rat forced swimming test. Eur Neuropsychopharmacol 2005, 15(6):593-599.
34. Hu B., Doods H., Treede R.D., Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009, 143:206-212.
35. Janowsky D.S., Overstreet D.H., Nurnberger J.I. Is cholinergic sensitivity a genetic marker for the affective disorders?. Am J Med Genet 1994, 54(4):335-344.
36. Janowsky D.S., El-Yousef M.K., Davis J.M. Acetylcholine and depression. Psychosom Med 1974, 36(3):248-257.
37. Ji C.X., Zhang J.J. Effect of scopolamine on depression in mice. Yao Xue Xue Bao 2011, 46(4):400-405.
38. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Investig 2005, 115:3104-3116.
39. Karl T., Cheng D., Garner B., Arnold J.C. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opin Therap Targets 2012, 16(4):407-420.
40. Knoppman D. Pharmacothephy for Alzheimer's disease. Curr Neurol Neurosci Rep 2001, 1:428-432.
41. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., et al. Expression of CB 1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007, 114:1055-1063.
42. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008, 105(2):751-756.
43. Kruk-Slomka M., Budzynska B., Biała G. Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 2012, 64(5):1066-1080.
44. Lagalwar S., Bordayo E.Z., Hoffmann K.L., Fawcett J.R., Frey W.H. Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 1999, 13:55-61.
45. Layman J.M., Milton A.S. Some actions of delta-1 tetrahydrocannabinol and cannabidiol at cholinergic junctions. Br J Pharmacol 1971, 41(2):379-380.
46. Le Foll B., Goldberg S.R. Rimonabant, a CB1 antagonist, block nicotine-conditioned place preference. NeuroReport 2004, 15:2139-2143.
47. Lichtman A.H., Martin B.R. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 1996, 126(2):125-131.
48. López-Valdés H.E., García-Colunga J. Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol Psychiatry 2001, 6(5):511-519.
49. Lucassen P.J1, Meerlo P., Naylor A.S., van Dam A.M., Dayer A.G., Fuchs E., et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol 2010, 20:1-17.
50. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001, 393(2):321-328.
51. Manrique-Garcia E., Zammit S., Dalman C., Hemmingsson T., Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry 2012, 12:112.
52. Marchalant Y., Cerbai F., Brothers H., Wenk G. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging 2008, 29:1894-1901.
53. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002, 80(3):448-456.
54. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159(4):379-387.
55. Micale V., Di Marzo V., Sulcova A., Wotjak C.T., Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther 2013, 138(1):18-37.
56. Mineur Y.S., Picciotto M.R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010, 31(12):580-586.
57. Mukhopadhyay S., Das S., Williams E.A., Moore D., Jones J.D., Zahm D.S. Lipopolysaccharide and cyclic AMP regulation of CB(2) cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. J Neuroimmunol 2006, 181(1-2):82-92.
58. Nakamura K., Tanaka Y. Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology 2001, 158:205-212.
59. Negash S., Xie S., Davatzikos C., Clark C.M., Trojanowski J.Q., Shaw L.M., et al. Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology. Alzheimers Dement 2013, 9(3):89-95.
60. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
61. Oinavi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs abuse and in depression. Ann NY Acad Sci 2008, 1139:434-449.
62. Overstreet D.H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 1993, 17:51-68.
63. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106.
64. Popik P., Krawczyk M., Kos T., Nalepa I., Kowalska M., Witarski T., et al. Nicotine produces antidepressant-like actions: behavioral and neurochemical evidence. Eur J Pharmacol 2005, 515:128-133.
65. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
66. Pucilowski O., Overstreet D.H., Rezvani A.H., Janowsky D.S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 1993, 54(6):1215-1220.
67. Renard C.E., Dailly E., David D.J., Hascoet M., Bourin M. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 2003, 17:449-455.
68. Roche M., Diamond M., Kelly J.P., Finn D.P. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 2006, 181(1-2):57-67.
69. Rodriguez De Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitell A., Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005, 40(1):2-14.
70. Ross R.A., Brockie H.C., Stevenson L.A., Murphy V.L., Templeton F., Makriyannis A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 1999, 126(3):66572.
71. Rutkowska M., Jachimeziuk O. Antidepressant properties of ACEA (arachidonyl-2-chloroethylamid), the selective agonist of CB1 receptors. Acta Pol Pharm 2004, 61:165-167.
72. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10(9):1110-1115.
73. Schatzberg A.F., Rothscild A.J., Langlais P.J., Bird E.D., Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985, 19(1):57-64.
74. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122(5):509-522.
75. Serra G., Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health 2007, 3:25.
76. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., et al. Antidepresant-like and anorectic effects of cannabinoid CB1 receptor inverse agonist AM 251 in mice. Behav Pharmacol 2003, 14(8):573-582.
77. Starkstein S.E., Mizrahi R., Power B.D. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatry 2008, 20(4):382-388.
78. Steffens M., Szabo B., Klar M., Rominger A., Zentner J., Feuerstein T.J. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience 2003, 120(2):455-465.
79. Suemaru K., Yasuda K., Cui R., Li B., Umeda K., Amano M., et al. Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice. Physiol Behav 2006, 88:545-549.
80. Swerdlow R.H. Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 2012, 22(3):182-194.
81. Tanveer R., Mcguinness N., Daniel S., Gowran A., Campbell V.A. Cannabinoid receptors and neurodegenerative diseases. Wiley Interdiscip Rev Membr Transp Signal 2012, 1(5):633-639.
82. Terranova J.P., Storme J.J., Lafon N., Peño A., Rinaldi-Carmona M. Improvement of memory in rodents by the selective CB1 cannabinoid antagonist, SR 141716. Psychopharmacology 1996, 126:165-172.
83. Tizabi Y., Overstreet D.H., Rezvani A.H., Louis V.A., Clark E., Janowsky D.S., et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 1999, 142:193-199.
84. Tzavara E.T., Wade M., Nomikos G.G. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 2003, 23(28):9374-9384.
85. Vaidya V.A., Fernandes K., Jha S. Regulation of adult hippocampal neurogenesis: relevance to depression. Expert Rev Neurotherapeutics 2007, 7(7):853-864.
86. Valjent E., Mitchell J.M., Besson M.J., Caboche J., Maldonado R. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002, 135:564-578.
87. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310(5746):329-332.
88. Vazquez-Palacios G., Bonilla-Jaime H., Velazquez-Moctezuma J. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with flouxetine. Pharmacol Biochem Behav 2004, 78:165-169.
89. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005, 81(2):331-342.
90. Witkin J.M., Tzavara E.T., Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005, 16(5-6):315-331.
91. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997, 20:92-98.